ISSN:
1573-0646
Keywords:
anthracycline
;
esorubicin
;
4′ deoxydoxorubicin
;
ovarian cancer
;
clinical trial
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00171850
Permalink